Genentech shares positive results from phase 3 trial for breast cancer treatment
Betsy Goodfellow | December 5, 2023 | News story | Research and Development | Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential treatment for patients with PIK3CA-mutated, hormone receptor (HC)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.
The trial met its primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone.
Overall survival (OS) data was immature at this point of analysis but a clear positive trend was observed, with follow-up expected to continue until the next analysis.
The drug combination was well tolerated, with adverse effects remaining consistent with the known safety profiles of all of the drugs. No new safety signals were observed.
“These pivotal study results for this inavolisib combination could represent a transformative medical advance for people with PIK3CA-mutated HR-positive breast cancer,” said Levi Garraway, MD, PhD, Genentech’s chief medical officer and head of Global Product Development. “We look forward to expanding our portfolio of breast cancer medicines into the HR-positive space and bringing this potentially best-in-class new treatment option to patients as quickly as possible.”
Betsy Goodfellow
Related Content
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
Curve Therapeutics’ CSO publishes research on HIF inhibition for cancer treatment
Curve Therapeutics has announced that its chief scientific officer, Professor Ali Tavassoli has published research …
